AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML
Open Access
- 1 February 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 107 (3) , 1166-1173
- https://doi.org/10.1182/blood-2005-06-2325
Abstract
The nonobese diabetic/severe combined immunodeficient (NOD/SCID) assay is the current model for assessment of human normal and leukemic stem cells. WKeywords
This publication has 39 references indexed in Scilit:
- Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotypeBlood, 2005
- CXCR4 Regulates Migration and Development of Human Acute Myelogenous Leukemia Stem Cells in Transplanted NOD/SCID MiceCancer Research, 2004
- Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulationBlood, 2004
- Engraftment of Acute Myeloid Leukemia in NOD/SCID Mice Is Independent of CXCR4 and Predicts Poor Patient SurvivalThe International Journal of Cell Cloning, 2004
- Human AML cells in NOD/SCID mice: engraftment potential and gene expressionLeukemia, 2002
- The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trialBlood, 2001
- Genomic structure of human FLT3: implications for mutational analysisBritish Journal of Haematology, 2001
- Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-β2 microglobulin–null miceJournal of Clinical Investigation, 2001
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958